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Abstract
Background: To analyze changes in incidence and outcomes of patients undergoing revision total hip arthroplasty
(RTHA) over an 8-year study period in Spain.
Methods: We selected all surgical admissions in individuals aged ≥ 40 years who underwent RTHA (ICD-9-CM
procedure code 81.53) between 2001 and 2008 from the Spanish National Hospital Discharge Database. Age- and
sex-specific incidence rates, Charlson co-morbidity index, length of stay (LOS), costs and in-hospital mortality (IHM)
were estimated for each year. Multivariate analyses were conducted to asses time trends.
Results: 32, 280 discharges of patients (13, 391 men/18, 889 women) having undergone RTHA were identified.
Overall crude incidence showed a small but significant increase from 20.2 to 21.8 RTHA per 100, 000 inhabitants
from 2001 to 2008 (p < 0.01).
The incidence increased for men (17.7 to 19.8 in 2008) but did not vary for women (22.3 in 2001 and 22.2 in 2008).
Greater increments were observed in patients older than 84 years and in the age group 75-84. In 2001, 19% of
RTHA patients had a Charlson Index ≥ 1 and this proportion rose to 24.6% in 2008 (p < 0.001). The ratio RTHA/THA
remained stable and around 20% in Spain along the entire period
The crude overall in-hospital mortality (IHM) increased from 1.16% in 2001 to 1.77% (p = 0.025) in 2008. For both
sexes the risk of death was higher with age, with the highest mortality rates found among those aged 85 or over.
After multivariate analysis no change was observed in IHM over time. The mean inflation adjusted cost per patient
increased by 78.3%, from 9, 375 to 16, 715 Euros from 2001 to 2008.
After controlling for possible confounders using Poisson regression models, we observed that the incidence of
RTHA hospitalizations significantly increased for men and women over the period 2001 to 2008 (IRR 1.10, 95% CI
1.03-1.18 and 1.08, 95% CI 1.02-1.14 respectively).
Conclusions: The crude incidence of RTHA in Spain showed a small but significant increase from 2001 to 2008
with concomitant reductions in LOS, significant increase in co-morbidities and cost per patient.
Keywords: Revision, Hip arthroplasty, Cost, Mortality, Outcome research, Osteoarthritis, Revision, Hospital, Charlson
Index, Discharge Database
Background
Although recent reports based on National Arthroplasty
Registries show that the overall 10-year survival of total
hip arthroplasty (THA) is over 90%, the burden of Revi-
sion Total Hip Arthroplasty (RTHA) is growing in
developed countries [1,2]. Patients undergoing RTHA
usually suffer from several co-morbidities, technical dif-
ficulties and complications requiring higher resource
utilization than THA [3-5].
Surveys from several countries have reported a contin-
ued growth in the use of THA and RTHA over the last
decades as a result of ageing populations, the extension of
indications and of the age range for this treatment [3-5].
In addition, the results and functional improvement of
RTHA seems to be inferior to THA with greater length
of hospital stay (LOS) and higher cost [6-9].
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comes between countries may provide information that
would help for understanding the differences as well as
aid for planning the provision of healthcare services
[10].
Unfortunately Spain does not have a national arthro-
plasty registry. In the absence of such a registry, the dis-
charge databases can provide a large alternative
information source to describe and analyze the trends
and characteristics of THA and RTHA at a national
level [11,12].
The aim of this study was to analyze national repre-
sentative data, collected thr o u g ht h eS p a n i s hH o s p i t a l
Discharge Database [13] from 2001 to 2008 to elucidate
changes in incidence; demographic characteristics; co-
morbidity profiles; LOS; costs; and, in-hospital mortality
(IHM) of patients undergoing RTHA.
Methods
According to the Spanish Health System Organization,
each physician must declare at the time of discharge all
diagnoses and procedures performed for each hospitali-
zation using the code of the International Classification
of Disease, 9th revision (ICD-9CM). This information is
collected by the Spanish National Hospital Database,
namely “Conjunto Mínimo Básico de Datos” (CMBD),
which compiles all the public and private hospital data
and covers more than 95% of hospital discharges [14].
The CMBD database includes patients’ variables (sex,
date of birth), date of admittance, date of discharge, dis-
charge destination (home, deceased or other health/
social institution), up to 14 discharge diagnosis and up
to 20 procedures performed during the admission.
Social or health institutions include nursing homes and
long-term care medical centers.
In Spain since 1999 the National Statistics Institute
has used the ICD-10 to codify the underlying cause of
death. But the CMBD has not been changed to the 10th
revision and the ICD-9 cm is still being used [13,14].
We included all surgical admissions (elective or emer-
gency admissions) in patients 40 years or over, who
received a RTHA procedure (ICD-9-CM procedure code
81.53) during 2001-2008. We calculated the yearly age-
and sex-specific incidence rates by dividing the number
of RTHA cases per year per sex and age group by the
corresponding population per group according to the
National Institute of Statistics (INE), reported on
December 31
st each year [15]. Incidence rates were
expressed per 100.000 inhabitants. The proportion of
patients that died during hospital admission (IHM),
LOS, and costs was also estimated for each year studied
using the number of RTHA as the denominator. Costs
were calculated using Diagnosis-Related Groups (DRG)
for the disease. DRG represents a medical-economic
entity concerning a set of diseases requiring analogous
management resources [16]. All costs shown are
adjusted for inflation over the same period in Spain
according to the National Institute for Statistics [17].
Spain has a universal public health system so every per-
son legally residing in or visiting Spain receives all medi-
cal and surgical treatment free of charge. As in most
European countries, the reimbursing system is based on
the DRG.
Clinical characteristics included information in overall
co-morbidity at the time of surgery, which was assessed
by computing the Charlson comorbidity index (CCI)
[18]. The CCI is not a tool routinely used in all hospital
patients, so we calculated the CCI for each patient
based on coded data available at the discharge register.
We divided patients into 3 categories: low index, which
corresponded to patients with no previously recorded
disease categories in the CCI; medium index, patients
with one or two disease categories; and high index,
patients with more than two disease categories. We
used these three cutting points, even though it is not
the classification suggested by literature, to make our
results comparable to other reports from Spain and to a
previous study on primary total hip arthroplasty using
the same methods [5,19].
We also analyzed if the total number of RTHA chan-
ged in relation to the number of Primary THA per-
formed by calculating the ratio RTHA/THA per year
and the time trend.
Statistical analysis
Quantitative variables were expressed as means, med-
ians, range and inter-quartile range (IQR). Qualitative
variables were expressed as frequencies and percentages.
Comparisons were done using the chi-square test, Fish-
er’s exact test, Student’s t-test, Wilcoxon rank-sum test,
ANOVA or Kruskal-Wallis test as appropriate. The mul-
tivariate analysis for time trends in the variables studied
was conducted using Poisson, lineal and logistic regres-
sion models adjusted by age, sex and other co-variables
when appropriate. Estimations were made using STATA
program and statistical significance was set at a <0 · 0 5
(two-tailed).
The cumulated and anonymised data were delivered
by the Ministry of Health, the official institute holding
the Spanish National Hospital Database. Thus, data pro-
tection was fully guaranteed. Given the anonymous and
m a n d a t o r yn a t u r eo ft h ed a t a ,t h er e q u i r e m e n tf o r
informed consent was not necessary.
Results
The Spanish population changed over the study period.
According to the Spanish National Statistics Institute
[15], in 2001 the population living in Spain was 41.12
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Page 2 of 10million; by 2008 the population it had increased to 46.16
million. The proportion of immigrant population
increased from 3.33% in 2001 to 11.42% in 2008. As a
consequence of this mainly young immigrant popula-
tion, the proportion of people aged 65 or over decreased
from 17.2% to 16.54% in this period.
From 2001 to 2008, we identified a total of 32, 280
patient discharges (13, 391 men and 18, 889 women)
that underwent a RTHA. Tabl e1a n dF i g u r e1d i s p l a y s
the total numbers and the incidence of RTHA per 100,
000 inhabitants in each year and according to age group
and gender.
The overall crude incidence increased from 20.2
RTHA to 21.1 RTHA per 100, 000 inhabitants from
2001 to 2008 (p < 0.001). The incidence of RTHA hos-
pitalizations has increased during the eight year study
period for men (17.8 in 2001 to 19.8 in 2008) and not
changed for women (22.3 in 2001 and 22.2 in 2008).
Among men, incidence significantly increased for
those aged 40-54, 75-84 and ≥ 85 years. Among women,
an increase was found among those aged 75-84 and
over 84 years, and a decrease was found in the 65-74
years category. The highest incidence for both sexes was
found in the 75-84 years category, followed by the 65-74
years category and the 85 or older category. However,
the greater increments were observed in the sub-groups
of patients older than 84 years and the sub-group 75-84
years.
Table 1 also shows the total number of RTHA and
THA and the ratio RTHA/THA per year. As we can
see, the percentages remained stable and around 20%
with no change overtime.
Time trends in the discharge destinations and CCI for
RTHA and primary THA are summarized in Table 2.
The results for primary THA are also shown.
The proportion of individuals with RTHA who were
discharged to a social or health institution rose signifi-
cantly from 4% in 2001 to 6.4% in 2008 (p < 0.001).
In 2001, 81% of RTHA patients had a Charlson Index
of 0, 17.8% of 1-2, and in 1.2% it was greater than two.
In 2008, the proportion of patients who underwent a
RTHA and had a Charlson Index of 1-2 or > 2 increased
to 22.1% and 2.5% respectively (p < 0.001). Figures for
CCI were very similar for revision and primary THA,
Table 1 Age and sex-specific incidence rates for RTHA and total number of RTHA and primary THA in Spain (2001-8)
2001 2002 2003 2004 2005 2006 2007 2008
Age Rate/100,
000
Rate/100,
000
Rate/100,
000
Rate/100,
000
Rate/100,
000
Rate/100,
000
Rate/100,
000
Rate/100,
000
P*
40-
54
Men 4.6 5.1 4.3 4.3 4.5 5.2 5.3 5.7 0.007
Women 3.1 3.3 2.9 2.8 2.9 3.1 3.3 3.2 0.540
50-
64
Men 14.3 12.4 14.9 14.9 13.5 14.5 15.2 15.2 0.100
Women 14.9 13.5 13.4 11.2 11.9 12.7 12.2 13.1 0.054
65-
74
Men 36.9 33.4 36.5 34.4 34.1 35.6 34.3 36.3 0.862
Women 43.8 42.7 44.3 44.3 38.9 42.4 38.4 37.5 <
0.001
75-
84
Men 40.6 44.6 44.2 48.6 54.0 51.9 52.3 55.2 <
0.001
Women 53.8 57.3 61.8 61.7 61.7 66.8 64.7 65.6 <
0.001
≥ 85 Men 19.3 22.3 21.8 22.0 25.2 26.1 22.9 30.0 <
0.001
Women 27.7 26.9 27.0 31.2 34.4 33.6 32.9 37.2 <
0.001
Total Men 17.8 17.3 18.0 18.0 18.3 18.9 18.8 19.8 0.107
Women 22.3 22.1 22.8 22.4 21.6 23.1 21.9 22.2 <
0.001
Both 20.2 19.9 20.6 20.4 20.1 21.1 20.4 21.1 0.016
Number of
RTHA
3, 713 3, 699 3, 912 3, 964 3, 992 4, 294 4, 242 4, 464
Number of
primary THA
18, 185 19, 029 19, 545 19, 733 20, 461 21, 176 21, 354 22, 308
Ratio RTHA/
THA %
20.42 19.44 20.02 20.09 19.51 20.28 19.87 20.01 0.077
Incidence rates (number of cases per year sex and age group/corresponding number of person in that population group that year)
*P value for time trend estimated using Poisson regression models
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patients discharged to a Health/social institution.
The mean LOS for RTHA admissions was 20.6 days in
2001 and showed a small but significant decrease to 19.1
days in 2008 (p < 0.01). A decreasing time trend in the
LOS was observed in both sexes, Table 3.
During the study period, total costs for RTHA
increased from 34.8 million to 74.6 million euros,
 
Figure 1 Incidence of RTHA per 100, 000 inhabitants in Spain from 2001 to 2008, according to age group and gender.
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Page 4 of 10however, the average costs per RTHA increased by
78.3%, from 9, 375 to 16, 715 euros. Women had higher
mean and total costs per RTHA than men trough all
the years analyzed (Table 3).
IHM rate trends according to sex- and age-groups are
shown in Table 4. The risk of death was higher with age
for both sexes. The overall IHM rate per RTHA
increased from 1.16% in 2001 to 1.77% (p = 0.025) in
2008 (1.4% in women and 0.8% in men in 2001 to 2.02%
in women and 1.44% in men in 2008). The highest mor-
tality rates were found among women and men aged 85
or over, nevertheless, there was a significant reduction
in male mortality rates in this older group (7.7% in 2001
and 3.5% in 2008) as compared to women (7.8% in 2001
and 10.7% in 2008).
As can be seen in Table 5 after controlling for pos-
sible confounders (age, sex and CCI), using Poisson
regression models, we observed that the incidence of
RTHA hospitalizations has significantly increased
from 2001 to 2008 for both men and women (IRR
1.10, 95% CI 1.03-1.18 and 1.08, 95% CI 1.02-1.14
respectively).
With regard to IHM, after adjusting the logistic
regression model, controlling by age and CCI, men and
women showed no significant changes in the risk of
death after RTHA from 2001 to 2008.
Table 2 Percentages of discharge destinations and Charlson comorbidity index of RTHA and primary THA patients
hospitalized in Spain (2001-2008)
2001 2002 2003 2004 2005 2006 2007 2008 P*
RTHA Discharge destinations* Home 96.0 95.2 95.5 94.5 94.4 94.3 94.8 93.6 < 0.001
Health/social institution) 4.0 4.8 4.5 5.5 5.6 5.7 5.2 6.4
Charlson comorbidity index Low 81.0 79.7 78.1 77.5 75.7 76.9 75.9 75.4 < 0.001
Medium 17.8 19.2 20.5 21.3 22.8 21.5 22.5 22.1
High 1.2 1.1 1.4 1.2 1.5 1.6 1.6 2.5
Primary THA Discharge destinations* Home 96.8 97.0 96.4 96.4 96.1 95.7 95.9 95.3 < 0.001
Health/social institution) 3.2 3.0 3.6 3.6 3.9 4.3 4.1 4.7
Charlson comorbidity index Low 81.0 81.2 79.9 79.4 79.2 78.7 77.9 78.5 < 0.001
Medium 18.4 18.1 19.3 19.9 19.9 20.4 21.3 20.4
High 0.6 0.7 0.8 0.7 0.9 0.9 0.8 1.1
*P value for time trend estimated using logistic regression adjusted by age and sex.
Table 3 Length of stay in days and hospital costs per patient for RTHA hospitalizations in Spain (2001-2008)
Year
2001 2002 2003 2004 2005 2006 2007 2008 p-value
Length of stay in days Men Mean 18.90 19.74 19.56 18.67 19.38 18.19 17.28 17.17 < 0.001
Median 15.00 14.00 14.00 13.00 13.00 13.00 12.00 12.00
IQR 12.00 12.00 13.00 13.00 13.00 11.00 10.00 11.00
Women Mean 21.81 20.80 20.57 19.99 20.68 20.16 19.81 20.53 0.015
Median 16.00 15.00 15.00 14.00 14.00 14.00 13.00 14.00
IQR 14.00 14.00 14.00 14.00 15.00 14.00 13.00 14.00
Both Mean 20.64 20.37 20.17 19.45 20.14 19.35 18.74 19.07 < 0.001
Median 15.00 15.00 14.00 14.00 14.00 14.00 13.00 13.00
IQR 12.00 14.00 14.00 13.00 14.00 13.00 13.00 14.00
Costs per patient (Euros) Men Mean 8, 565.91 9, 857.04 11, 038.01 11, 645.21 11, 663.85 15, 221.23 14, 944.87 15, 011.78 < 0.001
Median 6, 597.13 7, 256.20 7, 887.54 8, 228.87 7, 800.66 10, 779.02 11, 161.12 9, 986.17
IQR 4, 837.90 6, 344.27 7, 109.21 7, 641.10 , 688.20 9, 880.77 8, 370.84 9, 986.17
Women Mean 9, 923.12 10, 291.09 11, 508.02 12, 584.07 12, 334.93 16, 812.99 17, 186.13 18, 029.63 < 0.001
Median 7, 036.94 7, 320.32 8, 450.94 8, 319.59 8, 400.71 12, 575.53 12, 091.21 11, 650.53
IQR 6, 299.19 7, 320.32 7, 601.91 8, 590.88 9, 000.76 11, 095.98 11, 226.38 12, 482.71
Both Mean 9, 375.56 10, 116.96 11, 318.55 12, 200.62 12, 051.34 16, 153.89 16, 232.99 16, 715.40 < 0.001
Median 6, 914.72 7, 320.32 7, 988.47 8, 228.87 8, 400.71 11, 677.27 11, 206.75 11, 030.62
IQR 5, 717.52 6, 832.29 7, 409.53 8, 228.87 8, 400.71 9, 880.77 10, 379.35 11, 646.23
P value for time trend estimated using logistic and lineal regression models.
IQR Inter quartile range
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Page 5 of 10Table 4 In-Hospital Mortality, shown as percentage with standard error, after RTHA in Spain (2001-2008) according to
age group and sex
2001 2002 2003 2004 2005 2006 2007 2008 p
Age (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE)
40-54 Men 0.00 (0.00) 0.00 (0.00) 0.58 (0.01) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0, 473
Women 1.67 (1.17) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.72 (0.72) 0.66 (0.66) 0.67 (0.66) 0, 938
55-64 Men 0.00 (0.00) 0.82 (0.58) 0.67 (0.47) 0.00 (0.00) 0.35 (0.35) 0.00 (0.00) 0.00 (0.00) 1.45 (0.64) 0, 281
Women 0.32 (0.32) 0.00 (0.00) 0.00 (0.00) 0.41 (0.41) 0.00 (0.00) 0.68 (0.48) 0.00 (0.00) 0.63 (0.44) 0, 324
65-74 Men 0.94 (0.38) 0.51 (0.27) 0.47 (0.27) 1.00 (0.41) 0.68 (0.34) 0.49 (0.28) 0.86 (0.38) 1.14 (0.43) 0, 546
Women 0.55 (0.25) 0.23 (0.19) 0.33 (0.19) 0.66 (0.27) 0.63 (0.28) 0.47 (0.23) 0.78 (0.32) 0.81 (0.33) 0, 146
75-84 Men 0.82 (0.47) 1.48 (0.67) 1.90 (0.67) 1.45 (0.54) 2.52 (0.66) 2.16 (0.62) 2.25 (0.62) 2.07 (0.57) 0, 101
Women 1.73 (0.48) 1.65 (0.48) 2.05 (0.48) 1.76 (0.44) 1.18 (0.35) 1.15 (0.33) 0.97 (0.30) 1.58 (0.38) 0, 141
≥ 85 Men 7.69 (4.27) 8.33 (3.99) 8.33 (3.99) 10.00 (4.24) 13.33 (4.39) 3.03 (2.11) 11.29 (4.02) 3.45 (1.96) 0, 347
Women 7.75 (2.35) 6.06 (1.26) 2.21 (1.26) 6.79 (1.98) 2.15 (1.06) 3.68 (1.37) 4.59 (1.50) 10.68 (2.02) 0, 246
Total Men 0.80 (0.23) 1.01 (0.27) 1.14 (0.27) 1.11 (0.26) 1.60 (0.31) 0.96 (0.23) 1.39 (0.28) 1.44 (0.27) 0, 073
Women 1.40 (0.25) 1.04 (0.21) 1.03 (0.21) 1.45 (0.25) 0.87 (0.19) 1.03 (0.20) 1.07 (0.21) 2.02 (0.28) 0, 151
Total 1.16 (0.18) 1.03 (0.16) 1.07 (0.16) 1.31 (0.18) 1.18 (0.17) 1.00 (0.15) 1.20 (0.17) 1.77 (0.20) 0, 025
In-Hospital Mortality (IHM) (number of patients that died during the hospitalization/number of patients’ hospitalized)
SE Standard error
*P value for time trend estimated using logistic regression
Table 5 Multivariate analysis of trends and factors associated with incidence and in-hospital deaths after RTHA
INCIDENCE OF HOSPITALIZATIONS FOR RTHA IN-HOSPITAL DEATHS AFTER HOSPITALIZATIONS
FOR RTHA
Risk Rate Ratios (95% Confidence Intervals)* Odds Ratios (95% Confidence Intervals)
Men Women Both Men Women Both
Age 40-54 - - - - - -
55-64 2.92 (2.75-3.11) 4.07 (3.79-4.38) 3.36 (3.21-3.52) 6.35 (0.81-49.61) 0.59 (0.18-1.95) 1.54 (0.60-3.95)
65-74 7.14 (6.75-7.55) 13.20 (12.37-
14.09)
9.52 (9.13-9.92) 11.00 (1.51-
80.22)
1.24 (0.48-3.18) 2.88 (1.25-6.65)
75-84 10.02 (9.46-
10.61)
19.61 (18.38-
20.91)
13.89 (13.32-
14.48)
24.89 (3.46-
179.24)
3.47 (1.40-8.56) 7.54 (3.32-
17.08)
≥ 85 3.58 (3.23-3.97) 11.95 (11.03-
12.95)
7.18 (6.76-7.61) 85.48 (11.69-
625.13)
13.52 (5.41-
33.76)
29.90 (13.03-
68.60)
Sex Men NA NA - NA NA -
Women NA NA 1.13 (1.10-1.15) NA NA 0.95 (0.77-1.17)
Charlson comorbidity
index
0 - -- -- -
1-2 0.32 (0.30-0.33) 0.24 (0.23-0.25) 0.27 (0.26-0.28) 3.24 (2.28-4.59) 3.87 (2.94-5.10) 3.69 (2.96-4.58)
>2 0.028 (0.02-
0.03)
0.015 (0.01-
0.02)
0.021 (0.01-
0.02)
13.98 (9.00-
21.73)
15.66 (9.53-
25.75)
17.81 (12.69-
24.99)
YEAR 2001 - - - - - -
2002 0.98 (0.91-1.05) 1.00 (0.94-1.06) 0.99 (0.95-1.04) 1.26 (0.59-2.70) 0.71 (0.41-1.23) 0.85 (0.54-1.34)
2003 1.02 (0.95-1.09) 1.04 (0.98-1.10) 1.03 (0.98-1.08) 1.15 (0.55-2.40) 0.69 (0.40-1.20) 0.83 (0.53-1.28)
2004 1.02 (0.95-1.10) 1.02 (0.96-1.08) 1.02 (0.98-1.07) 1.16 (0.56-2.40) 0.91 (0.55-1.51) 0.97 (0.64-1.48)
2005 1.06 (0.99-1.13) 0.99 (0.93-1.04) 1.01 (0.97-1.06) 1.55 (0.78-3.07) 0.50 (0.28-0.88) 0.81 (0.53-1.25)
2006 1.08 (1.01-1.16) 1.06 (1.00-1.12) 1.07 (1.02-1.12) 1.02 (0.49-2.15) 0.56 (0.32-0.95) 0.68 (0.44-1.06)
2007 1.04 (0.97-1.12) 1.07 (1.00-1.13) 1.04 (1.00-1.09) 1.46 (0.73-2.91) 0.60 (0.35-1.03) 0.85 (0.56-1.28)
2008 1.10 (1.03-1.18) 1.08(1.02-1.14) 1.08 (1.03-1.12) 1.29 (0.65-2.55) 1.06 (0.67-1.69) 1.12 (0.76-1.66)
Calculated using multivariate Poisson regression Dependent variable: “Incidence of hospitalizations for RTHA”.
† Calculated using logistic regression. Dependent variable: “In hospital death after hospitalizations for RTHA”
The independent variables included in the models are those shown in the table.
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CCI increased.
Discussion
In this population based study involving in32, 280 cases,
we found a small but significant increase in the inci-
dence of RTHA from 2001 to 2008 in the Spanish popu-
lation, from 20.2 to 21.1 procedures per 100, 000
inhabitants (p < 0.01). This represents a 3.75% overall
increase, which is similar to other reports in developed
countries [1].
In this period a total of 161, 791 discharges of patients
having undergone primary total hip arthroplasty were
identified and the overall crude incidence increased
from 99 to 105 THA per 100, 000 inhabitants (p <
0.001) [19].
Kurtz and Mowat analyzed the National Hospital Dis-
charge Survey (NHDS) of the USA, 1990 through 2002,
to study the changes in the revision burden. The rate of
RTHA increased by 3.7 procedures per 100, 000 persons
over a 10 year period [1].
In the United States and Canada the revision burden,
which refers to the percentage of revision hip replace-
ments relative to the total number of primary and revi-
sion hip replacements, stayed roughly the same in the
USA (14%-17% from 1993 to 2005) and in Canada
(11%-13% from 2001 to 2006) [6], reflecting an increase
in the absolute number of revisions as the number of
primary procedures also increased.
This same trend is observed in some National Regis-
tries. In Norway the revisions constituted 12.3% of all the
operations in 2003, 13.6% in 2007 and 14% in 2008 [20].
In 2009, the number of hip replacements reported to
the Australian Registry increased by 1, 100 (3.4%) com-
pared to 2008. Primary THA increased by 4.0% and
RTHA by 1.1%. From 2003 to 2009 primary total hip
replacement increased by 32.5% and revision hip repla-
cement 9.3%. Remarkably, revision hip replacement as a
proportion of all hip replacement procedures declined
from 13.0% in 2003 to 11.2% in 2009 [21].
In Spain the ratio RTHA/THA has remained stable
with figures around 20% from 2001 to 2008. The
equivalent percentages for the Norwegian Arthroplasty
Registry were 14.94% (922/6170) in 2001 and 16.37%
(1114/6804) in 2008 [20].In Australia in 2004 the ratio
was19.25% (3494/18153) decreasing to 16.63% (3677/
22109) in 2008 [21]
In our study the results of the Poisson regression ana-
lysis confirm that the increase in incidence of RTHA in
men and also in women became greater after adjusting
for potential confounders (age, sex and CCI). Although
all groups increased in incidence those patients aged 75-
84 or 65-74 experienced the highest (13.9 and 9.5 with
95% interval confidence of 13.3-14.5 and 9.1-9.9,
respectively). Other studies using multivariate models
have reached the same conclusions, verifying that the
increase in incidence of RTHA is not only a conse-
quence of population growth or ageing [3,4,22].
In a recent study Cram et al, in an observational
cohort of 1, 453, 493 Medicare beneficiaries who under-
went THA between 1991 and 2008 in the USA,
observed that the mean age for patients increased from
74.1 to 75.1 years (P < 0.001). [23]. In that same popula-
tion and time period, among 348 596 subjects who
underwent RTHA, the mean age also raised from 75.8
to 77.3 years (p < 0.001). [23].
In Spain, the number of high-risk surgical patients has
increased over the last 8 years as shown by the analysis
of the CCI. In 2001, 19% of patients had a Charlson
Index of 1-2 or > 2. In 2008, the proportion of patients
who had undergone a RTHA and had Charlson Index of
1-2 or > 2 had increased to 24.6% (p < 0.001). This
same trend has been previously described in other stu-
dies and in the present series in the same period in
THA [12,19,24].
A higher severity of illness store has been reported as
predictive of a higher resource utilization for both pri-
mary and revision arthroplasty [25].
Our co-morbidity index figures for primary THA and
RTHA are surprisingly similar. Cram et al [23] reported
a significant mean increase in the number of comorbid
illnesses per patient (from 1.0 to 2.0 for THA and 1.1 to
2.3 for RTHA) [23]. The similar morbidity index
observed in our patients undergoing primary and revi-
sion THA could be explained by survival (only healthier
subjects survive long enough to need a revision) and
selection (surgeons only conduct RTHA among those
patients with low co-morbidities) bias. Further studies
should be conducted to verify this.
LOS decreased from an average of 20.6 days in 2001
to 19.1 days in 2008 in Spain (p < 0.01), which is a
small but relevant change.
I nt h es a m ep e r i o d ,t h eL O Sf o rT H As i g n i f i c a n t l y
decreased from an average of 13 days in 2001 to 10.45
days in 2008 [19].
The mean nationwide LOS for Spain is longer than
that described in other countries although a wide varia-
bility has been reported [23,26].
As also suggested by other authors, we hypothesize
that the reasons for observing a decrease in the Spanish
LOS overtime may include: the presence of a larger rate
of specialized departments using more efficient means
to rehabilitate and discharge patients and an increased
rate of discharges to short and long-term care facilities
[26-28]. After adjusting by age and sex, our rate of
patients that were discharge to health or social institu-
tions significantly rose from 4% to 6.4% from 2001 to
2008.
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period increased by 114.4%, from 34.8 million Euros to
74.6 million Euros. After adjusting for inflation, the
average costs per patient increased by 78.3%, from 9,
375 to 16, 715 Euros. The total costs of primary THA
In Spain during this period increased by 75%, from
120.6 million Euros to 211.34 million Euros [19].
Stargardt studied the variations in the cost of THA
between and within nine member states of the European
Union (EU), including Spain. The main cost drivers
were found to be implants (34% of total cost on average)
and ward costs (20.9% of total cost on average) [29].
More complicated revisions, like those requiring bone
grafting, exchange of both components or specific com-
plications, like periprosthetic fractures or infections,
require higher resource utilization than easier ones
[25,30-33]. Even if we don’t have data detailing the rea-
son for revision we believe that the use of specialised
‘revision-implants’ is in part responsible of the large
increase in the average cost per patient overtime in Spain.
The overall IHM after RTHA in Spain ranged from
1.16% in 2001 to 1.77% (p: 0.025) in 2008 (1.40% in
women and 0.80% in men in 2001 and 2.02% in women
and 1.44% in men in 2008).
Zhan and Kaczmarek screened the hospital discharge
abstracts National Hospital Discharge Survey (NHDS) of
five states of the EU during the year 2003. Their
reported IHM rate was 0.84% and their rate of readmis-
sion, for any cause, within thirty days was 8.48%.
Advanced age and co-morbid diseases were associated
with worse outcomes [34].
In RTHA, prognostic factors related to higher mortal-
ity rates or complications may not be as clearly stated as
in THA. Older age and high CCI may be more consis-
tent but others like complexity of the revision, infected
RTHA, poor preoperative functional status or female
sex also seem to be important. These prognostic factors
should help to optimize indications for THA and to
reduce the already staggering, yet growing, burden of
RTHA in developed countries, compared to THA, with
greater LOS and higher cost [11,22,30,35-38].
To the best of our knowledge this is the first study in
Spain regarding changes in the incidence, demographic
characteristics, co-morbidity profiles, and in-hospital out-
comes of patients undergoing RTHA. In the absence of a
National Registry for Arthroplasty the incidence, IHM
rates and cost estimation reported in this study provide
the best available information. The main strength of the
current study lies in a large sample size and standardized
methodology maintained over the study period.
Nevertheless, the present study presents some limita-
tions. First, a potential source of bias comes from rely-
ing on administrative registri e sa ss e v e r a ld i s c r e p a n c i e s
between administrative data and audited and validated
clinical data have been suggested [39,40].
In Spain the CNBD was implemented in 1996 by the
Ministry of Health in liaison with all of the autonomous
communities. From that time efforts were made to
improve the quality of the information including: peri-
odic publications; mandatory educational programs for
the persons responsible for the codification in the hospi-
tals and periodical external quality control audits. Pre-
vious Spanish studies have assessed the validity of
CMBD data using medical records as a reference,
reporting that the CMBD is reliable for diagnosis and
for estimating adjusted mortality rates. [41,42].
Second, even if administrative data generally agrees
with patient chart data for recording of comorbidities, it
has been found that comorbidities tend to be under-
reported in administrative data [43-45].
This could explain the large healthy population found in
our study, based on our CCI. With regard to the use of the
Charlson index to measure comorbidities, Burgos E et al
conducted an investigation to assess the predictive value of
six functional status and/or surgical risk scoring systems,
including the anesthesiologic risk assessment instrument
(ASA) and the Charlson index, with regard to serious com-
plications after hip fracture surgery in the elderly. They
found that all the scoring system reached a sufficient predic-
tive value with regard to serious post-operative complica-
tions [46]. However the similarities and differences between
the Charlson comorbidity index and other commonly use
score such as the ASA classification are discussed by Wea-
ver et al. These authors found that among patient under-
going joint arthroplasties the discrepancy between the
comorbidity index and the ASA was striking [47].
Lastly, outcomes were limited to the variables coded.
The lack of differentiation between types of RTHA proce-
dures in the current ICD-9-CM procedure coding system
limits the utility of these codes in evaluating differences in
patient and procedure characteristics in large public data.
Other confounding relevant variables such as surgeon,
hospital volume, cause leading to revision or the percen-
tage of one-stage and two-stage revisions could not be
analyzed as these variables are not collected in the data-
base This lack of information about different brands thus
unable to pick-up specific implant-related failures, com-
pared with the National Joint Registries [20,21].
Therefore, outcomes such as LOS and discharge destina-
tion may have been influenced by other covariates differ-
ent from postoperative complications. In such a scenario,
only IHM or LOS can be used to draw direct conclusions
on the complication rate in the current study.
As noted above, because we used anonymised data
it is impossible to detect double registrations, readmis-
sions and transfers using the CMBD. Furthermore,
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number of double registrations, readmissions and trans-
fers among patients undergoing a hip arthroplasty so a
correction factor including this information could not
be used to adjust the data. This is relevant because pre-
vious studies conducted in other countries have shown
that the number of readmissions and transfers may have
changed over time and may differ with age and sex
[48,49].
We believe that, notwithstanding its limitations the
CMBD is a valid instrument to conduct epidemiological
studies and has previously been used for this purpose,
including by other authors. [20,50,51].
Although DRG have been a useful patient classifica-
tion system for hospital cost analysis, DRG present a
series of limitations [52,53]. Riley in a recent review
concludes that because administrative data have been
collected for other purposes it is therefore not necessa-
rily in a format that is intelligible or convenient to
researchers. Furthermore, coding of diagnoses and pro-
cedures are more closely related to billing requirements
than to medical records.
Conclusions
In conclusion the present study indicates a small but
significant increase in the crude and adjusted incidence
of RTHA in Spain from 2001 to 2008 in line with
results observed in other countries. We also found
reductions in LOS with a significant increase in cost per
patient. The health profile of the patient undergoing
RTHA seems to be worsening in Spain. These results
may reflect broadening of the indication criteria for
these procedures in conjunction with the natural failures
of THA implanted in the previous decades.
This time trend may be useful for planning future
resources and to optimize indications and proper patient
selection.
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